food industry glp 1 Impact of GLP-1 Weight Loss Drugs on Choices The Impact of GLP-1 Drugs

WeightWatchers Clinic WeightWatchers now offers telehealth access to weight loss medication alongside its familiar points-based nutrition system

Even intentional weight loss correlates with increased depressive symptomatology among overweight or obese adults in the United States, Journal of Affective Disorders Report (2022) Cross-sectional, case-control and longitudinal associations between exposure to glucagon-like peptide-1 receptor agonists and the dispensing of antidepressants, Diabetes, Obesity, and Metabolism (2024) Diabetes and mental health, CDC (2024) Effect of antidepressants on glucagon-like peptide-1 receptor agonist-related weight loss, Journal of Pharmacy Technology (2022) Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline: A post hoc subgroup analysis, Obesity (2024) Increased incident rates of antidepressant use during the COVID-19 pandemic: interrupted time-series analysis of a nationally representative sample, Psychological Medicine (2022) KFF Health Tracking Poll May 2024: The publics use and views of GLP-1 drugs, KFF (2024) Obese patients taking antidepressants lost weight on semaglutide, Cleveland Clinic Journal of Medicine (2023) Overweight, obesity, and depression: A systematic review and meta-analysis of longitudinal studies, JAMA Psychiatry (2010) Ozempic dosing, Ozempic Wegovy dosing schedule, Wegovy Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

Reviewed by Pieter Cohen, MD, Contributor Peptides are getting a lot of attention on social media, purporting to support everything from muscle growth and skin health to improved energy, cognitive function, and sleep quality

Circadian Rhythm Research: Applied in studies investigating molecular regulation of sleepwake cycle signaling mechanisms

For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions

For type 2 diabetes management , NICE guideline NG28 recommends GLP-1 receptor agonists as a treatment option when: Metformin and other oral medications have not achieved adequate glycaemic control The patient has a BMI of 35 kg/m or higher (or lower thresholds for people from South Asian and related minority ethnic backgrounds) Weight loss would benefit other obesity-related comorbidities Continuation of GLP-1 therapy for diabetes typically requires demonstration of beneficial response, defined as a reduction in HbA1c of at least 11 mmol/mol (1.0%) and weight loss of at least 3% of initial body weight at six months